23J Stock Chart & Stats
€6.60
--
Market closed
€6.60
--
Day’s Range― - ―
52-Week Range€5.68 - €22.00
Previous CloseN/A
VolumeN/A
Average Volume (3M)0.00
Market Cap
€110.19M
Enterprise Value-€50.24M
Total Cash (Recent Filing)€63.85M
Total Debt (Recent Filing)€0.00
Price to Earnings (P/E)―
Beta0.18
Next Earnings
Aug 17, 2026EPS Estimate
-1.23Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-23.59
Shares Outstanding8,967,693
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)-9.53K
Price to Sales (P/S)0.00
P/FCF Ratio-426.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€27.34Price Target Upside314.20% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)-4.76
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Targeted Antibody Platform For Misfolded ProteinsProMIS’s discovery focus on antibodies that bind pathogenic conformations while sparing normal forms is a durable competitive edge in neurodegeneration. High target selectivity can improve safety and efficacy, support differentiation versus broad-spectrum approaches, and enable platform application across Alzheimer’s and ALS, enhancing long‑term licensing and partnership appeal.
Debt-free Balance Sheet With Meaningful Equity BaseHaving no debt and a tangible equity buffer reduces near-term liquidity risk and preserves strategic flexibility for a clinical-stage biotech. This capital structure lowers fixed obligations, making it easier to prioritize R&D spend, negotiate partnerships, and manage clinical timelines without the immediate pressure of debt servicing, improving survivability through development cycles.
Shareholder-approved Incentive Plan Supports Talent RetentionExpanding the equity incentive reserve is a structural move to retain and recruit scientific and executive talent, aligning management with long-term goals. For a small clinical-stage company, stronger compensation tools improve continuity of R&D leadership and increase attractiveness to collaborators, which supports execution of multi-year development programs.
Bears Say
Pre-revenue With Sizable, Persistent Cash BurnSustained multi-year operating losses and large negative free cash flow are structural constraints for a development-stage biotech. Ongoing burn increases dependency on external funding, raises dilution risk, and can force prioritization or delay of programs if capital markets or partner deals are unavailable, undermining long-term program continuity.
Business Model Dependent On External FinancingsReliance on equity financings and potential milestone/license deals rather than operating revenue is a structural vulnerability. Access to capital is subject to market and investor sentiment, which can delay trials or force unfavorable terms. Long-term development plans hinge on successful raises or partnerships, adding execution and funding risk.
Inconsistent Equity History And Weak Returns On EquityA history of negative equity periods and persistently negative ROE signals past recapitalizations and limited ability to generate shareholder returns from operations. This pattern indicates balance sheet volatility and could impair investor confidence, limit bargaining power with partners, and increase future dilution risk when raising needed development capital.
ProMIS Neurosciences News
23J FAQ
What was ProMIS Neurosciences Inc.’s price range in the past 12 months?
ProMIS Neurosciences Inc. lowest stock price was €5.68 and its highest was €22.00 in the past 12 months.
What is ProMIS Neurosciences Inc.’s market cap?
ProMIS Neurosciences Inc.’s market cap is €110.19M.
When is ProMIS Neurosciences Inc.’s upcoming earnings report date?
ProMIS Neurosciences Inc.’s upcoming earnings report date is Aug 17, 2026 which is in 23 days.
How were ProMIS Neurosciences Inc.’s earnings last quarter?
ProMIS Neurosciences Inc. released its earnings results on May 12, 2026. The company reported -€1.101 earnings per share for the quarter, missing the consensus estimate of -€0.926 by -€0.175.
Is ProMIS Neurosciences Inc. overvalued?
According to Wall Street analysts ProMIS Neurosciences Inc.’s price is currently Undervalued.
Does ProMIS Neurosciences Inc. pay dividends?
ProMIS Neurosciences Inc. does not currently pay dividends.
What is ProMIS Neurosciences Inc.’s EPS estimate?
ProMIS Neurosciences Inc.’s EPS estimate is -1.23.
How many shares outstanding does ProMIS Neurosciences Inc. have?
ProMIS Neurosciences Inc. has 8,967,693 shares outstanding.
What happened to ProMIS Neurosciences Inc.’s price movement after its last earnings report?
ProMIS Neurosciences Inc. reported an EPS of -€1.101 in its last earnings report, missing expectations of -€0.926. Following the earnings report the stock price went up 10.256%.
Which hedge fund is a major shareholder of ProMIS Neurosciences Inc.?
Currently, no hedge funds are holding shares in DE:23J
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
ProMIS Neurosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€27.34 (314.20% Upside)
€27.34 (314.20% Upside)
Blogger Sentiment
Bullish
DE:23J Sentiment 70%
Sector Average 65%
Sector Average 65%
Insider Transactions
Bought Shares
Worth €39.6K over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
-42.67%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
393.98%
Trailing 12-Months
Company Description
ProMIS Neurosciences Inc.
ProMIS Neurosciences, Inc. is a Canadian biotechnology firm dedicated to creating targeted therapeutic solutions for debilitating neurodegenerative conditions such as Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), and multiple system atrophy (MSA). The company leverages a unique computational discovery platform, utilizing its ProMIS and Collective Coordinates algorithms, to identify novel, disease-specific targets – known as epitopes – located on the surface of misfolded proteins. Its pipeline features several promising drug candidates, including PMN310, a monoclonal antibody designed to address toxic oligomers implicated in Alzheimer's disease. Another candidate, PMN267, targets superoxide dismutase 1 and TAR-DNA binding protein 43 in ALS, and alpha-synuclein associated with Parkinson's disease and Lewy body dementia. Finally, PMN442 is a monoclonal antibody aimed at toxic alpha-synuclein oligomers and seeding fibrils relevant to multiple system atrophy. Established in 2004, the company changed its name from Amorfix Life Sciences Ltd. to ProMIS Neurosciences, Inc. in July 2015. Its corporate headquarters are situated in Toronto, Canada.
23J Stock 12 Month Forecast
Average Price Target
€27.34
▲(314.20% Upside)